阅读说明：本技术 一种治疗子宫腺肌病的药物及应用 (Medicine for treating adenomyosis and application ) 是由 廖红 李芳� 程玉芬 于 2020-07-08 设计创作，主要内容包括：本发明属于临床药物技术领域,公开了一种治疗子宫腺肌病的药物及应用,准备地诺孕素及左炔诺孕酮宫内缓释系统；采取HIFU消融联合地诺孕素及左炔诺孕酮宫内缓释系统综合治疗。本发明采取HIFU消融联合地诺孕素及左炔诺孕酮宫内缓释系统(LNG-IUS)综合治疗子宫腺肌病。分析HIFU消融联合地诺孕素和LNG-IUS治疗子宫腺肌病患者的有效率及复发率,并分析HIFU消融治疗子宫腺肌病症状的相关因素,旨在为临床上HIFU消融治疗子宫腺肌病提供参考。(The invention belongs to the technical field of clinical medicines, and discloses a medicine for treating adenomyosis and application thereof, wherein a dienogest and levonorgestrel intrauterine sustained-release system is prepared; adopts HIFU ablation combined with dienogest and levonorgestrel intrauterine sustained release system for comprehensive treatment. The invention adopts HIFU ablation combined with dienogest and levonorgestrel intrauterine sustained release system (LNG-IUS) to comprehensively treat adenomyosis. The effective rate and the recurrence rate of patients with adenomyosis treated by HIFU ablation combined with dienogest and LNG-IUS are analyzed, and relevant factors of symptoms of adenomyosis treated by HIFU ablation are analyzed, so that the reference is provided for clinical HIFU ablation treatment of adenomyosis.)

1. The medicine for treating adenomyosis is characterized in that the medicine for treating adenomyosis is dienogest and levonorgestrel intrauterine sustained-release system.

2. The method for applying the drug for treating adenomyosis according to claim 1, wherein the method for applying the drug for treating adenomyosis comprises:

firstly, preparing a dienogest and levonorgestrel intrauterine sustained-release system;

and step two, adopting HIFU ablation combined with dienogest and levonorgestrel intrauterine sustained release system for comprehensive treatment.

3. The use of the medicament for the treatment of adenomyosis of claim 1 in the treatment of adenomyosis by HIFU ablation.

Technical Field

The invention belongs to the technical field of clinical medicines, and particularly relates to a medicine for treating adenomyosis and application thereof.

Background

Currently, adenomyosis is characterized by a localized or diffuse enlargement of the uterus caused by invasion of endometrial glands and interstitium into the myometrium; is a common benign disease of uterus, and common clinical symptoms such as dysmenorrheal, abnormal vaginal bleeding, infertility, chronic pelvic pain, compression and the like. The High Intensity Focused Ultrasound (HIFU) ablation technology is a new noninvasive surgical technology, and is currently applied to the treatment of benign diseases such as uterine fibroids, and therefore, a new means is provided for noninvasive conservative treatment of adenomyosis. However, because the ectopic endometrium is characterized by diffuse growth, unclear boundaries of adenomyosis focuses and the like, HIFU ablation is a conservative treatment method for adenomyosis, and although research proves that the treatment effect is better, the recurrence rate is still higher.

As a chronic disease, the treatment of adenomyosis is mainly drug therapy rather than surgical therapy, emphasizing long-term management. The drug therapy comprises gonadotropin releasing hormone agonist (GnRH-a), levonorgestrel slow release system in utero (LNG-IUS), oral progestogen and the like. High Intensity Focused Ultrasound (HIFU) is mainly used to control the symptoms of adenomyosis dysmenorrhea. The long-term management of the patient with adenomyosis is combined with drug treatment after HIFU treatment, so that the recurrence rate can be effectively reduced. Literature reports post-HIFU combination therapy with GnRH-a and LNG-IUS. Since GnRH-a can not be used for a long time, the number of uses is also specified in the guidelines (3-6), and LNG-IUS is easy to fall off in the case of uterus. Dienogest is a newly introduced medicine for treating adenomyosis, has the pharmacological advantages of natural and synthetic progestogens, has high progestogens activity, only combines with progestogens receptors, has no estrogen, antiestrogen and androgen activity, has weak anti-gonadotropins effect, but has the effects of slightly inhibiting ovulation and slightly reducing estrogen level. In addition, dienogest has the effects of inhibiting endometrial cell proliferation and reducing nerve growth factor and nerve fiber density. Recent researches show that the dienogest has definite curative effect on endometriosis, but the application of dienogest in treating adenomyosis is still in the initial stage. Compared with GnRH-a, the research shows that the effect of the dienogest on relieving pain related to adenomyosis is similar to GnRHA, and the long-term application of the dienogest can effectively relieve the symptoms of pain related to adenomyosis, so that the dienogest is a more effective drug treatment means for patients with adenomyosis who have no fertility requirement and want to retain the uterus or do not require fertility temporarily, and can be used for a long time compared with GnRH-a. At this time, the volume of uterus is reduced to 2 months of pregnancy by using dienogest, and then LNG-IUS is placed to achieve better treatment effect.

Through the above analysis, the problems and defects of the prior art are as follows: the existing high-intensity focused ultrasound ablation method has higher recurrence rate.

The difficulty in solving the above problems and defects is: as a chronic disease, the treatment of adenomyosis is mainly drug therapy rather than surgical therapy, emphasizing long-term management. The drug therapy comprises gonadotropin releasing hormone agonist (GnRH-a), levonorgestrel slow release system in utero (LNG-IUS), oral progestogen and the like. High Intensity Focused Ultrasound (HIFU) is mainly used to control the symptoms of adenomyosis dysmenorrhea. The long-term management of the patient with adenomyosis is combined with drug treatment after HIFU treatment, so that the recurrence rate can be effectively reduced. Literature reports post-HIFU combination therapy with GnRH-a and LNG-IUS. Since GnRH-a can not be used for a long time, the number of uses is also specified in the guidelines (3-6), and LNG-IUS is easy to fall off in the case of uterus.

The significance of solving the problems and the defects is as follows: dienogest is a newly introduced drug for treating adenomyosis, and can be used for a long time compared with GnRH-a. At this time, the volume of uterus is reduced to 2 months of pregnancy by using dienogest, and then LNG-IUS is placed to achieve better treatment effect.

Disclosure of Invention

Aiming at the problems in the prior art, the invention provides a medicine for treating adenomyosis and application thereof.

The invention is realized in such a way that the medicine for treating adenomyosis is dienogest and levonorgestrel slow release system (LNG-IUS) in utero.

The invention also aims to provide an application method of the medicament for treating adenomyosis, which comprises the following steps:

firstly, preparing a dienogest and levonorgestrel intrauterine sustained-release system;

and step two, adopting HIFU ablation combined with dienogest and levonorgestrel intrauterine sustained release system to comprehensively treat adenomyosis.

The invention also aims to provide application of the medicine for treating adenomyosis in preparing medicines for treating adenomyosis through HIFU ablation.

By combining all the technical schemes, the invention has the advantages and positive effects that: the invention adopts HIFU ablation combined with dienogest and levonorgestrel intrauterine sustained release system (LNG-IUS) to comprehensively treat adenomyosis. The effective rate and the recurrence rate of patients with adenomyosis treated by HIFU ablation combined with dienogest and LNG-IUS are analyzed, and the method aims to provide reference for clinical HIFU ablation treatment of adenomyosis.

Drawings

In order to more clearly illustrate the technical solutions of the embodiments of the present application, the drawings needed to be used in the embodiments of the present application will be briefly described below, and it is obvious that the drawings described below are only some embodiments of the present application, and it is obvious for those skilled in the art that other drawings can be obtained from the drawings without creative efforts.

FIG. 1 is a flow chart of the method for applying the medicine for treating adenomyosis provided by the embodiment of the invention.

Fig. 2 is a schematic diagram of a statistical analysis provided by an embodiment of the present invention.

Fig. 3 is a pre-operation image of an ultrasound contrast image before and after a HIFU treatment of adenomyosis provided by an embodiment of the present invention.

Fig. 4 is a postoperative image of an ultrasound contrast image before and after a HIFU treatment of adenomyosis according to an embodiment of the present invention.

Detailed Description

In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is further described in detail with reference to the following embodiments. It should be understood that the specific embodiments described herein are merely illustrative of the invention and are not intended to limit the invention.

Aiming at the problems in the prior art, the invention provides a medicament for treating adenomyosis and application thereof, and the invention is described in detail below with reference to the accompanying drawings.

As shown in fig. 1, the application method of the drug for treating adenomyosis provided by the invention comprises the following steps:

s101: preparing a dienogest and levonorgestrel intrauterine sustained-release system;

s102: adopts HIFU ablation combined with dienogest and levonorgestrel intrauterine sustained release system (LNG-IUS) to comprehensively treat adenomyosis.

The technical solution of the present invention is further described with reference to the following specific examples.